CA3099737A1 - Pharmaceutical salts of pyrimidine derivatives and method of treating disorders - Google Patents

Pharmaceutical salts of pyrimidine derivatives and method of treating disorders Download PDF

Info

Publication number
CA3099737A1
CA3099737A1 CA3099737A CA3099737A CA3099737A1 CA 3099737 A1 CA3099737 A1 CA 3099737A1 CA 3099737 A CA3099737 A CA 3099737A CA 3099737 A CA3099737 A CA 3099737A CA 3099737 A1 CA3099737 A1 CA 3099737A1
Authority
CA
Canada
Prior art keywords
compound
int
methyl
salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099737A
Other languages
English (en)
French (fr)
Inventor
Landon J. DURAK
Marianne Langston
Pradeep Kumar Sharma
Thai Hiep Nguyen
Shuanglian LI
Xiaoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of CA3099737A1 publication Critical patent/CA3099737A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3099737A 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders Pending CA3099737A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
US62/671,182 2018-05-14
US62/671,166 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Publications (1)

Publication Number Publication Date
CA3099737A1 true CA3099737A1 (en) 2019-11-21

Family

ID=68540756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099737A Pending CA3099737A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Country Status (11)

Country Link
US (1) US12084431B2 (enExample)
EP (2) EP4234547A3 (enExample)
JP (2) JP2021523208A (enExample)
KR (1) KR20200144579A (enExample)
CN (1) CN112313223A (enExample)
AU (1) AU2019269372A1 (enExample)
BR (1) BR112020023107A2 (enExample)
CA (1) CA3099737A1 (enExample)
MX (1) MX2020012063A (enExample)
TW (1) TWI831780B (enExample)
WO (1) WO2019222093A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR20220011663A (ko) * 2019-05-22 2022-01-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 인돌 유도체-함유 억제제, 이의 제조 방법 또는 이의 적용
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor
MX2024000261A (es) * 2021-08-06 2024-03-14 Abbisko Therapeutics Co Ltd Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788629T2 (de) 1986-03-31 1994-04-28 Rhone Poulenc Bv Neue malonsäurederivate und zusammensetzungen, die sie enthalten, zur verzögerung des pflanzenwachstums.
JP2749578B2 (ja) 1986-03-31 1998-05-13 ローヌープーラン・ネーデルランド・ベー・ベー 相乗的植物成長調節剤組成物
JPS63503070A (ja) 1986-03-31 1988-11-10 ローヌープーラン・ネーデルランド・ベー・ベー マロン酸誘導体化合物の作物収穫量を増大させるための使用
WO2000006555A1 (en) 1998-07-30 2000-02-10 American Home Products Corporation Substituted quinazoline derivatives
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2003097855A2 (en) 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP2008510719A (ja) 2004-08-19 2008-04-10 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
JP2012517448A (ja) 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
US9840517B2 (en) 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
JP2017507983A (ja) 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
MY186839A (en) * 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
PL3205650T3 (pl) 2014-10-11 2021-12-06 Shanghai Hansoh Biomedical Co., Ltd. Inhibitor EGFR i jego otrzymywanie i zastosowanie
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂

Also Published As

Publication number Publication date
WO2019222093A1 (en) 2019-11-21
CN112313223A (zh) 2021-02-02
EP3793993A4 (en) 2022-01-05
TWI831780B (zh) 2024-02-11
AU2019269372A1 (en) 2020-11-26
US20210309640A1 (en) 2021-10-07
TW202015687A (zh) 2020-05-01
KR20200144579A (ko) 2020-12-29
EP4234547A2 (en) 2023-08-30
JP2024051160A (ja) 2024-04-10
MX2020012063A (es) 2021-04-13
EP3793993A1 (en) 2021-03-24
BR112020023107A2 (pt) 2021-02-02
US12084431B2 (en) 2024-09-10
JP2021523208A (ja) 2021-09-02
EP4234547A3 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
KR102744039B1 (ko) 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR102090453B1 (ko) 상피 성장 인자 수용체 키나제 억제제의 염
CN104066735B (zh) 作为akt激酶抑制剂的取代的咪唑并吡嗪
JP6517979B2 (ja) １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
CN110759908B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
JP2019509990A (ja) チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途
KR20160121602A (ko) 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법
WO2016011195A1 (en) Th-302 solid forms and methods related thereto
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
CN114829370B (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
IL271628B2 (en) A new salt of n-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1h -pyrazolo[3,4-h]quinazoline-3-carboxamide, its preparation and formulations containing it
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
CN117794902A (zh) ErbB和BTK抑制剂的新型药用盐和多晶型形式
HK40046158A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
KR20260023568A (ko) Enpp1 억제제의 결정형
JP2023526235A (ja) 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
HK40050133A (en) Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
HK40050133B (en) Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
KR20220132811A (ko) 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240510

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250516

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251031

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251231